Loading…
Changes in viral hepatitis B screening practices over time in West African HIV clinics
We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa. A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who star...
Saved in:
| Published in: | Médecine et maladies infectieuses 2017-10, Vol.47 (6), p.394-400 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553 |
| container_end_page | 400 |
| container_issue | 6 |
| container_start_page | 394 |
| container_title | Médecine et maladies infectieuses |
| container_volume | 47 |
| creator | Coffie, P.A. Patassi, A. Doumbia, A. Bado, G. Messou, E. Minga, A. Allah-Kouadio, E. Zannou, D.M. Seydi, M. Kakou, A.R. Dabis, F. Wandeler, G. |
| description | We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa.
A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression.
A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P |
| doi_str_mv | 10.1016/j.medmal.2017.04.011 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1903170531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0399077X1730611X</els_id><sourcerecordid>1903170531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553</originalsourceid><addsrcrecordid>eNp9kE1P4zAQhi3ECrqFf4CQJS5ckh07iV1fkKBiAanSXvi6WY4zKa4Sp9hpJf79uirsYQ_MZQ7zvDOjh5AzBjkDJn6t8h6b3nQ5ByZzKHNg7IBMmBQqE0LBIZlAoVQGUr4ek58xrgB4YuGIHPNZVVZCVhPyPH8zfomROk-3LpiOvuHajG50kd7QaAOid35J18HY0dkEDlsMdHQ97iIvGEd63QZnjaf3D8_Uds47G0_Ij9Z0EU8_-5Q8_b59nN9niz93D_PrRWYLIcZMNaBa3pqmlHVTq0JgySWz0tS2FkrYVqLkCg1IUc4qJq1SvG5nTTlrRM2rqpiSy_3edRjeN-kZ3btoseuMx2ETNVNQMAlVwRJ68R-6GjbBp-80Z6l4VQieqHJP2TDEGLDV6-B6Ez40A73zrld6713vvGsodfKeYuefyzd1Gv8LfYlOwNUewGRj6zDoaB16i40LaEfdDO77C38BOeKUaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2111125362</pqid></control><display><type>article</type><title>Changes in viral hepatitis B screening practices over time in West African HIV clinics</title><source>ScienceDirect Journals</source><creator>Coffie, P.A. ; Patassi, A. ; Doumbia, A. ; Bado, G. ; Messou, E. ; Minga, A. ; Allah-Kouadio, E. ; Zannou, D.M. ; Seydi, M. ; Kakou, A.R. ; Dabis, F. ; Wandeler, G.</creator><creatorcontrib>Coffie, P.A. ; Patassi, A. ; Doumbia, A. ; Bado, G. ; Messou, E. ; Minga, A. ; Allah-Kouadio, E. ; Zannou, D.M. ; Seydi, M. ; Kakou, A.R. ; Dabis, F. ; Wandeler, G.</creatorcontrib><description>We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa.
A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression.
A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01–1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09–3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5–24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen.
Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.
Décrire les pratiques de dépistage de l’hépatite B au cours du temps chez les patients infectés par le VIH en Afrique de l’Ouest.
Une enquête a été menée dans les centres urbains de prise en charge du VIH en Côte d’Ivoire (3 sites), Bénin, Burkina Faso, Sénégal et Togo (1 site chacun). Parmi les patients ayant été mis sous traitement antirétroviral entre 2010 et 2012, 100 ont été tirés au sort chaque année dans chaque clinique. Les informations ont été recueillies à partir des dossiers médicaux. Les facteurs associés au dépistage de l’hépatite B ont été recherchés par régression logistique.
Au total, 2097 patients ont été inclus (âge médian de 37 ans, 65,4 % de femmes). Le dépistage de l’hépatite B a été réalisé chez 313 (14,9 %) patients, avec une augmentation au cours du temps (de 10,6 % en 2010 à 18,9 % en 2012, p<0,001), et une variation entre les centres. Un âge>45 ans (rapport de cotes ajusté : 1,34 [1,01–1,77]) et une activité génératrice de revenus (rapport de cotes ajusté : 1,82 [1,09–3,03]) étaient associés au dépistage de l’hépatite B. La prévalence de l’hépatite B chronique (AgHBs+) était de 19,8 % (15,5–24,7) et 82,3 % des co-infectés étaient traités par ténofovir.
Entre 2010 et 2012, le dépistage de l’hépatite B chez les patients infectés par le VIH était faible. La disponibilité croissante des tests rapides de recherche de l’AgHBs et du ténofovir devrait améliorer ce dépistage.</description><identifier>ISSN: 0399-077X</identifier><identifier>EISSN: 1769-6690</identifier><identifier>DOI: 10.1016/j.medmal.2017.04.011</identifier><identifier>PMID: 28545675</identifier><language>eng</language><publisher>France: Elsevier SAS</publisher><subject>Adult ; Africa, Western - epidemiology ; Afrique subsaharienne ; Alanine Transaminase - blood ; Anti-Retroviral Agents - administration & dosage ; Antiretroviral agents ; CD4 Lymphocyte Count ; Confidence intervals ; Demographics ; Dépistage ; Female ; HBV ; Hepatitis ; Hepatitis B ; Hepatitis B - complications ; Hepatitis B - diagnosis ; Hepatitis B - epidemiology ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV-1 - isolation & purification ; HIV-2 - isolation & purification ; HIV-infected patients ; Human immunodeficiency virus ; Humans ; Male ; Mass Screening - trends ; Medical screening ; Medical treatment ; Middle Aged ; Patients ; Patients infectés par le VIH ; Prevalence ; Regression analysis ; Retrospective Studies ; Risk Factors ; Screening ; Statistical analysis ; Sub-Saharan Africa ; Surveys and Questionnaires ; Tenofovir ; VHB</subject><ispartof>Médecine et maladies infectieuses, 2017-10, Vol.47 (6), p.394-400</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Oct 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553</citedby><cites>FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553</cites><orcidid>0000-0002-6486-2991</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28545675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coffie, P.A.</creatorcontrib><creatorcontrib>Patassi, A.</creatorcontrib><creatorcontrib>Doumbia, A.</creatorcontrib><creatorcontrib>Bado, G.</creatorcontrib><creatorcontrib>Messou, E.</creatorcontrib><creatorcontrib>Minga, A.</creatorcontrib><creatorcontrib>Allah-Kouadio, E.</creatorcontrib><creatorcontrib>Zannou, D.M.</creatorcontrib><creatorcontrib>Seydi, M.</creatorcontrib><creatorcontrib>Kakou, A.R.</creatorcontrib><creatorcontrib>Dabis, F.</creatorcontrib><creatorcontrib>Wandeler, G.</creatorcontrib><title>Changes in viral hepatitis B screening practices over time in West African HIV clinics</title><title>Médecine et maladies infectieuses</title><addtitle>Med Mal Infect</addtitle><description>We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa.
A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression.
A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01–1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09–3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5–24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen.
Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.
Décrire les pratiques de dépistage de l’hépatite B au cours du temps chez les patients infectés par le VIH en Afrique de l’Ouest.
Une enquête a été menée dans les centres urbains de prise en charge du VIH en Côte d’Ivoire (3 sites), Bénin, Burkina Faso, Sénégal et Togo (1 site chacun). Parmi les patients ayant été mis sous traitement antirétroviral entre 2010 et 2012, 100 ont été tirés au sort chaque année dans chaque clinique. Les informations ont été recueillies à partir des dossiers médicaux. Les facteurs associés au dépistage de l’hépatite B ont été recherchés par régression logistique.
Au total, 2097 patients ont été inclus (âge médian de 37 ans, 65,4 % de femmes). Le dépistage de l’hépatite B a été réalisé chez 313 (14,9 %) patients, avec une augmentation au cours du temps (de 10,6 % en 2010 à 18,9 % en 2012, p<0,001), et une variation entre les centres. Un âge>45 ans (rapport de cotes ajusté : 1,34 [1,01–1,77]) et une activité génératrice de revenus (rapport de cotes ajusté : 1,82 [1,09–3,03]) étaient associés au dépistage de l’hépatite B. La prévalence de l’hépatite B chronique (AgHBs+) était de 19,8 % (15,5–24,7) et 82,3 % des co-infectés étaient traités par ténofovir.
Entre 2010 et 2012, le dépistage de l’hépatite B chez les patients infectés par le VIH était faible. La disponibilité croissante des tests rapides de recherche de l’AgHBs et du ténofovir devrait améliorer ce dépistage.</description><subject>Adult</subject><subject>Africa, Western - epidemiology</subject><subject>Afrique subsaharienne</subject><subject>Alanine Transaminase - blood</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Antiretroviral agents</subject><subject>CD4 Lymphocyte Count</subject><subject>Confidence intervals</subject><subject>Demographics</subject><subject>Dépistage</subject><subject>Female</subject><subject>HBV</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - diagnosis</subject><subject>Hepatitis B - epidemiology</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1 - isolation & purification</subject><subject>HIV-2 - isolation & purification</subject><subject>HIV-infected patients</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Mass Screening - trends</subject><subject>Medical screening</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Patients infectés par le VIH</subject><subject>Prevalence</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Screening</subject><subject>Statistical analysis</subject><subject>Sub-Saharan Africa</subject><subject>Surveys and Questionnaires</subject><subject>Tenofovir</subject><subject>VHB</subject><issn>0399-077X</issn><issn>1769-6690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1P4zAQhi3ECrqFf4CQJS5ckh07iV1fkKBiAanSXvi6WY4zKa4Sp9hpJf79uirsYQ_MZQ7zvDOjh5AzBjkDJn6t8h6b3nQ5ByZzKHNg7IBMmBQqE0LBIZlAoVQGUr4ek58xrgB4YuGIHPNZVVZCVhPyPH8zfomROk-3LpiOvuHajG50kd7QaAOid35J18HY0dkEDlsMdHQ97iIvGEd63QZnjaf3D8_Uds47G0_Ij9Z0EU8_-5Q8_b59nN9niz93D_PrRWYLIcZMNaBa3pqmlHVTq0JgySWz0tS2FkrYVqLkCg1IUc4qJq1SvG5nTTlrRM2rqpiSy_3edRjeN-kZ3btoseuMx2ETNVNQMAlVwRJ68R-6GjbBp-80Z6l4VQieqHJP2TDEGLDV6-B6Ez40A73zrld6713vvGsodfKeYuefyzd1Gv8LfYlOwNUewGRj6zDoaB16i40LaEfdDO77C38BOeKUaA</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Coffie, P.A.</creator><creator>Patassi, A.</creator><creator>Doumbia, A.</creator><creator>Bado, G.</creator><creator>Messou, E.</creator><creator>Minga, A.</creator><creator>Allah-Kouadio, E.</creator><creator>Zannou, D.M.</creator><creator>Seydi, M.</creator><creator>Kakou, A.R.</creator><creator>Dabis, F.</creator><creator>Wandeler, G.</creator><general>Elsevier SAS</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6486-2991</orcidid></search><sort><creationdate>201710</creationdate><title>Changes in viral hepatitis B screening practices over time in West African HIV clinics</title><author>Coffie, P.A. ; Patassi, A. ; Doumbia, A. ; Bado, G. ; Messou, E. ; Minga, A. ; Allah-Kouadio, E. ; Zannou, D.M. ; Seydi, M. ; Kakou, A.R. ; Dabis, F. ; Wandeler, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Africa, Western - epidemiology</topic><topic>Afrique subsaharienne</topic><topic>Alanine Transaminase - blood</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Antiretroviral agents</topic><topic>CD4 Lymphocyte Count</topic><topic>Confidence intervals</topic><topic>Demographics</topic><topic>Dépistage</topic><topic>Female</topic><topic>HBV</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - diagnosis</topic><topic>Hepatitis B - epidemiology</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1 - isolation & purification</topic><topic>HIV-2 - isolation & purification</topic><topic>HIV-infected patients</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Mass Screening - trends</topic><topic>Medical screening</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Patients infectés par le VIH</topic><topic>Prevalence</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Screening</topic><topic>Statistical analysis</topic><topic>Sub-Saharan Africa</topic><topic>Surveys and Questionnaires</topic><topic>Tenofovir</topic><topic>VHB</topic><toplevel>online_resources</toplevel><creatorcontrib>Coffie, P.A.</creatorcontrib><creatorcontrib>Patassi, A.</creatorcontrib><creatorcontrib>Doumbia, A.</creatorcontrib><creatorcontrib>Bado, G.</creatorcontrib><creatorcontrib>Messou, E.</creatorcontrib><creatorcontrib>Minga, A.</creatorcontrib><creatorcontrib>Allah-Kouadio, E.</creatorcontrib><creatorcontrib>Zannou, D.M.</creatorcontrib><creatorcontrib>Seydi, M.</creatorcontrib><creatorcontrib>Kakou, A.R.</creatorcontrib><creatorcontrib>Dabis, F.</creatorcontrib><creatorcontrib>Wandeler, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Médecine et maladies infectieuses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coffie, P.A.</au><au>Patassi, A.</au><au>Doumbia, A.</au><au>Bado, G.</au><au>Messou, E.</au><au>Minga, A.</au><au>Allah-Kouadio, E.</au><au>Zannou, D.M.</au><au>Seydi, M.</au><au>Kakou, A.R.</au><au>Dabis, F.</au><au>Wandeler, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in viral hepatitis B screening practices over time in West African HIV clinics</atitle><jtitle>Médecine et maladies infectieuses</jtitle><addtitle>Med Mal Infect</addtitle><date>2017-10</date><risdate>2017</risdate><volume>47</volume><issue>6</issue><spage>394</spage><epage>400</epage><pages>394-400</pages><issn>0399-077X</issn><eissn>1769-6690</eissn><abstract>We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa.
A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression.
A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01–1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09–3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5–24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen.
Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.
Décrire les pratiques de dépistage de l’hépatite B au cours du temps chez les patients infectés par le VIH en Afrique de l’Ouest.
Une enquête a été menée dans les centres urbains de prise en charge du VIH en Côte d’Ivoire (3 sites), Bénin, Burkina Faso, Sénégal et Togo (1 site chacun). Parmi les patients ayant été mis sous traitement antirétroviral entre 2010 et 2012, 100 ont été tirés au sort chaque année dans chaque clinique. Les informations ont été recueillies à partir des dossiers médicaux. Les facteurs associés au dépistage de l’hépatite B ont été recherchés par régression logistique.
Au total, 2097 patients ont été inclus (âge médian de 37 ans, 65,4 % de femmes). Le dépistage de l’hépatite B a été réalisé chez 313 (14,9 %) patients, avec une augmentation au cours du temps (de 10,6 % en 2010 à 18,9 % en 2012, p<0,001), et une variation entre les centres. Un âge>45 ans (rapport de cotes ajusté : 1,34 [1,01–1,77]) et une activité génératrice de revenus (rapport de cotes ajusté : 1,82 [1,09–3,03]) étaient associés au dépistage de l’hépatite B. La prévalence de l’hépatite B chronique (AgHBs+) était de 19,8 % (15,5–24,7) et 82,3 % des co-infectés étaient traités par ténofovir.
Entre 2010 et 2012, le dépistage de l’hépatite B chez les patients infectés par le VIH était faible. La disponibilité croissante des tests rapides de recherche de l’AgHBs et du ténofovir devrait améliorer ce dépistage.</abstract><cop>France</cop><pub>Elsevier SAS</pub><pmid>28545675</pmid><doi>10.1016/j.medmal.2017.04.011</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6486-2991</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0399-077X |
| ispartof | Médecine et maladies infectieuses, 2017-10, Vol.47 (6), p.394-400 |
| issn | 0399-077X 1769-6690 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1903170531 |
| source | ScienceDirect Journals |
| subjects | Adult Africa, Western - epidemiology Afrique subsaharienne Alanine Transaminase - blood Anti-Retroviral Agents - administration & dosage Antiretroviral agents CD4 Lymphocyte Count Confidence intervals Demographics Dépistage Female HBV Hepatitis Hepatitis B Hepatitis B - complications Hepatitis B - diagnosis Hepatitis B - epidemiology Hepatitis B surface antigen Hepatitis B Surface Antigens - blood HIV HIV Infections - complications HIV Infections - drug therapy HIV-1 - isolation & purification HIV-2 - isolation & purification HIV-infected patients Human immunodeficiency virus Humans Male Mass Screening - trends Medical screening Medical treatment Middle Aged Patients Patients infectés par le VIH Prevalence Regression analysis Retrospective Studies Risk Factors Screening Statistical analysis Sub-Saharan Africa Surveys and Questionnaires Tenofovir VHB |
| title | Changes in viral hepatitis B screening practices over time in West African HIV clinics |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20viral%20hepatitis%20B%20screening%20practices%20over%20time%20in%20West%20African%20HIV%20clinics&rft.jtitle=Me%CC%81decine%20et%20maladies%20infectieuses&rft.au=Coffie,%20P.A.&rft.date=2017-10&rft.volume=47&rft.issue=6&rft.spage=394&rft.epage=400&rft.pages=394-400&rft.issn=0399-077X&rft.eissn=1769-6690&rft_id=info:doi/10.1016/j.medmal.2017.04.011&rft_dat=%3Cproquest_cross%3E1903170531%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-9d09f2fad47bdb936e4271c7abcb696cf7e729ea07648517c992bf8d48d6b2553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2111125362&rft_id=info:pmid/28545675&rfr_iscdi=true |